Vaxcyte, Inc. Common Stock(PCVX)

Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership.

PCVX iron condor setups PCVX expected move PCVX IV rank history PCVX Fibonacci levels PCVX insider trading

Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.

PCVX $58.47 —
Snapshot
$58.47
52-Week Range
$29.50 – $65.00
YTD
+25.86%
IV Rank (30D)
2.1
Straddle Price
$7.27
P/C Vol Ratio
1.16
Market Cap
$8.6B
Fair Value
MODEL: LONG

A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.

  • DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
  • Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
  • DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
  • P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
  • Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
  • Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
  • Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
  • Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
10-yr Treasury (rf)4.70%
Beta vs SPY1.00
Cost of Equity (CAPM)10.20% (VRP-adj)
WACC10.17%
Volatility Risk Premium+39.8pp (IV − HV30), ERP adj +50bps
Effective Tax Rate21.0%
Rev. Growth (YoY, DCF input)+3.0%
DCF Horizon5 years explicit + fade
Forward Tilt (NTM/TTM)×1.03 (applied to P/E, EV/EBITDA, P/S)
Free Cash Flow (TTM)$-0.8B
Return on Equity (TTM)-31.6%
Book / Price39.1% — banking bias active (P/B is primary)
Debt / Equity0.00
Quality Score1/6 — cyclical/struggling (5y DCF)
SMA 50$53.39 (Market Anchor value)
SMA 20 / Bollinger Mid$55.87
Bollinger Width / SMA2020.3% (drives anchor stability)
Net Debt$-0.3B
Market Cap$8B
Peers used for multiples: BIIB, MRNA, NBIX (SIC-code peers; ETF co-membership was sector-incoherent)
Model Conviction
40%
20-Day Fair Value
≈ by Sep 4, 2026
$60.57
α +3.5% rank 44%
40-Day Fair Value
≈ by Oct 5, 2026
$65.31
α +11.6% rank 58%
60-Day Fair Value
≈ by Nov 3, 2026
$61.18
α +4.5% rank 60%
MethodImplied PriceWeightDetail
DCF n/a 0%
DDM (Gordon) n/a 0%
Peer P/E n/a 0%
Peer EV/EBITDA n/a 0%
Peer P/B $73.72 29% median 3.4× · 3 peers
Peer P/S n/a 0% median 5.0× · 3 peers
Market Anchor (SMA50) $53.39 71% stability 49% (BB-width)
Options Expected (B-L 30d) n/a 0%
As of 2026-08-06 · updated
Info
Industry (SIC)
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) (2836)
Exchange
XNAS
Market Cap
$8.6B

Vaxcyte Inc is a clinical-stage vaccine company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It uses the XpressCF cell-free protein synthesis platform to develop potentially superior and novel conjugate and protein vaccine candidates for adult and pediatric indications. The company's product pipeline includes: VAX-31, VAX-24, and VAX-XL PCV vaccine candidates; VAX-A1, a Novel Group A Strep Vaccine; and VAX-GI, a Novel Shigella Vaccine, among others, in their different stages of development.

Summary
—
composite
—
No summary data available for this symbol yet.

Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.

Chart
Seasonality
MonthAvg ReturnYears of Data
Jan -1.02% 6
Feb +3.46% 6
Mar -11.48% 6
Apr +0.17% 6
May +4.52% 6
Jun +3.26% 6
Jul +1.37% 6
Aug +9.57% 6
Sep +0.92% 5
Oct +19.94% 5
Nov -0.56% 5
Dec +9.29% 5
Technical Indicators

Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.

Trend Indicators
  • SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
  • EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
  • MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
  • ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
  • +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
  • RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
  • Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
  • Williams %R — inverted scale: <−80 oversold, >−20 overbought.

Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.

Volume & Volatility
  • Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
  • OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
  • Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
  • ATR / True Range — average daily $ move; sizing and stop-loss reference.
  • HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.

Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →

Trend Indicators

SMA 20: $55.82
SMA 50: $53.71
SMA 200: $52.38
Current: $58.29
EMA 12: $56.07
EMA 26: $55.61
MACD: 0.4628 | Signal: 0.1680
BULLISH
ADX (14): 21.34
WEAK TREND
+DI: 25.66
−DI: 11.73

Momentum Oscillators

RSI (14): 57.77
NEUTRAL
Stoch %K: 80.56
Stoch %D: 60.46
Williams %R: -14.54

Volume & Volatility

BB Upper: $58.74
BB Lower: $52.89
NEUTRAL
OBV: -13,901,558
Vol SMA 20: 891,289
Vol ROC: -19.51%
ATR: $2.42
True Range: $1.59
HV 20: 42.7%
HV 30: 48.1%
HV 60: 47.1%

Data Summary

Data Points: 500
Last Updated:
Date Range: 2024-08-09T00:00:00 – 2026-08-10T00:00:00
AI Analysis

Here is the LLM Stock Analysis Report for PCVX:

Executive Summary

Overall assessment: NEUTRAL with confidence level (6/10)

Key drivers and primary risks:

  • Recent positive news headlines and strong technical signals have driven the stock higher, but volatility remains moderate.
  • The company's pneumococcal vaccine program has shown promise in recent studies, which could drive future growth.
  • Risks include potential regulatory hurdles and competition from established players.

Recent news sentiment impact: The majority of recent news headlines are positive (4 out of 6), with a neutral headline from the industry publication Benzinga. This suggests that investor sentiment is generally optimistic.

Technical Analysis

Trend Direction: Short-term (1-4 weeks): Uptrend, Medium-term (1-3 months): Uptrend, Long-term (3-12 months): Downtrend

Support/Resistance Levels: Key price levels from moving averages and technical patterns: + SMA 20: $55.82 + SMA 50: $53.71 + SMA 200: $52.38 + Upper Bollinger Band: $58.74 + Lower Bollinger Band: $52.89

Momentum Signals: * RSI interpretation (overbought >70, oversold <30, neutral 30-70): Neutral (57.77) * MACD signal (bullish/bearish crossover): Bullish * Bollinger Bands position (squeeze, breakout, mean reversion): Mean reversion

Volume Analysis: Volume trends and institutional interest signals: + Volume SMA 20: 891289.75 + On-Balance Volume (OBV): -13901558.88 + Volume Rate of Change: -19.51%

News & Sentiment Analysis

Recent Headlines Summary: The majority of recent news headlines are positive, highlighting the company's pneumococcal vaccine program and financing activities.

Sentiment Assessment: Aggregate news sentiment is Positive (4 out of 6).

Catalyst Identification: Upcoming earnings release and continued progress in the pneumococcal vaccine program could drive future growth.

Market Narrative: The positive news headlines have driven the stock higher, but volatility remains moderate. The market narrative suggests that investors are optimistic about the company's prospects.

Risk & Volatility Assessment

Beta Interpretation: Beta: 0.89 (vs SPY) - indicates a relatively stable stock with low risk relative to the market.

Volatility Regime: Current vs historical volatility levels: + Historical Volatility (HV30): 48.1% + IV Premium vs HV30: 33.3% (positive = implied richer than realized) + Stock Volatility: 0.46

Options Market Signals: IV Rank: 2.1% (Low - shows if volatility is historically high/low), Current IV: 64.1%, Expected Move: $7.27 (39 DTE)

Market Context & Positioning

Sector Performance: Relative strength vs sector/market: + Sector: Healthcare + Market: S&P 500 (0.89 beta, moderate volatility)

Institutional Activity: Volume patterns suggesting institutional interest: + Volume SMA 20: 891289.75 + On-Balance Volume (OBV): -13901558.88

Correlation Analysis: How stock moves relative to market (R-squared interpretation): + R-squared: 0.25 (low correlation, high volatility)

Relative Valuation: Position within trading range: + Current Price: $58.29 + SMA 20: $55.82 + Upper Bollinger Band: $58.74

Key Levels & Action Items

Critical Price Levels: Support/resistance to monitor: + Lower Bollinger Band: $52.89 + SMA 50: $53.71 + SMA 200: $52.38

Breakout/Breakdown Levels: Technical levels that could trigger significant moves: + Upper Bollinger Band: $58.74

Time-Sensitive Catalysts: Earnings release and continued progress in the pneumococcal vaccine program.

Risk Management: Stop-loss levels and position sizing considerations: + Use a stop-loss order at $55.82 (SMA 20) to limit potential losses. + Consider reducing position size if IV Rank falls below 1% or IV Premium vs HV30 increases above 50%.

Please let me know if you would like me to modify anything!

Generated
News
Earnings History
7 of 8 under expected move
Avg Expected Move
12.73%
Avg Actual Move
5.03%
Each row pairs the pre-earnings straddle-implied expected move with the realized close-to-close move. Sorted oldest first.
Earnings Date Timing Expected Move Actual Move Ratio Outcome
2024-11-05 After-Close 6.25% 3.24% 0.52x Within
2025-02-25 After-Close 19.09% 0.18% 0.01x Within
2025-05-07 After-Close 14.02% 8.72% 0.62x Within
2025-08-06 After-Close 11.74% 9.06% 0.77x Within
2025-11-04 After-Close 19.83% 2.49% 0.13x Within
2026-02-24 After-Close 12.37% 1.70% 0.14x Within
2026-05-06 After-Close 8.36% 9.84% 1.18x Exceeded
2026-08-05 After-Close 10.15% 5.01% 0.49x Within
Options Activity
IV Rank (30D)
2.1
IV Rank (7D)
68.8
Avg IV
64.1%
Straddle (30D)
$7.27
Straddle (7D)
$4.10
P/C Volume
1.16
Spread Scanner GPU
Full Algorithm Docs ↗

Each spread is ranked by a composite score built in three stages. Full documentation →

Stage 1 — Base Score (GPU scanner)

score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.

Stage 2 — Skew Adjustment (±25% cap)

RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.

Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
  • RSI <40 bullish / >60 bearish
  • MACD crossover + histogram trend
  • Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
  • Stochastic %K <20 / >80
  • Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
  • Blended ATR + straddle expected-move penalty
  • Bollinger Band signal (+ counter-trend penalty)
  • BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
  • IV rank ≥ 75 → strong boost for credit spreads
  • IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
  • Min open interest across all legs
  • OI < 100 → −0.10 · OI < 500 → −0.05

score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →

Enter a ticker to scan for optimal spread opportunities.

Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.

Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Metric:
Wing vs ATM
IV(put wing) − IV(ATM), in vol points

How much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.

  • Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
  • Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
  • Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
  • Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each side

Which side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.

  • Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
  • Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
  • Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
  • Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together

Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:

  • High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
  • Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
  • Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d —
— pts EXTREME
ATM — / Wing —
30 DTE / 10d —
— pts EXTREME
ATM — / Wing —

Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.

Volatility Surface

Enter a ticker to render the implied volatility surface.

Volatility Smile

Enter a ticker to render the implied volatility smile.

IV Rank (7 DTE)
IV Rank (30 DTE)
Straddle Price (30 DTE)
Beta Analysis
Beta (1Y vs SPY)
0.89
Correlation (SPY)
24.7%
R²
0.06
Ann. Volatility
46.3%
SPY Volatility
12.9%

Moderate volatility - stock generally follows market

Beta & Alpha Over Time
Institutional Ownership (13F)
Latest filings — 2026-06-30
Diluted shares outstanding: 136,956,611 (as of 2026-03-31)

Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.

  • Shares — long equity positions in this name, aggregated across share classes.
  • Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
  • % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
  • Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.

Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.

338 filers157,781,889 shares$8.14B value115.21% of float
# Filer Shares Value % of Total % of Float Period
1 JANUS HENDERSON GROUP PLC 16,575,875 $960.23M 11.79% 12.10% 2026-03-31
2 FMR LLC Custodian 16,492,861 $958.40M 11.77% 12.04% 2026-03-31
3 RA CAPITAL MANAGEMENT, L.P. 11,474,599 $666.79M 8.19% 8.38% 2026-03-31
4 BlackRock, Inc. Custodian 10,971,816 $637.57M 7.83% 8.01% 2026-03-31
5 VANGUARD GROUP INC Custodian 12,193,986 $562.63M 6.91% 8.90% 2025-12-31
6 WELLINGTON MANAGEMENT GROUP LLP Custodian 5,614,597 $326.26M 4.01% 4.10% 2026-03-31
7 Paradigm Biocapital Advisors LP 4,793,020 $278.52M 3.42% 3.50% 2026-03-31
8 STATE STREET CORP 4,440,519 $258.04M 3.17% 3.24% 2026-03-31
9 Deep Track Capital, LP 4,300,000 $249.87M 3.07% 3.14% 2026-03-31
10 WESTFIELD CAPITAL MANAGEMENT CO LP 3,646,138 $211.88M 2.60% 2.66% 2026-03-31
11 GEODE CAPITAL MANAGEMENT, LLC Custodian 3,201,283 $186.06M 2.28% 2.34% 2026-03-31
12 Kynam Capital Management, LP 2,922,335 $169.82M 2.08% 2.13% 2026-03-31
13 D. E. Shaw & Co., Inc. Custodian 2,865,318 $166.50M 2.04% 2.09% 2026-03-31
14 Caligan Partners LP 2,060,719 $119.75M 1.47% 1.50% 2026-03-31
15 JENNISON ASSOCIATES LLC 1,698,011 $98.67M 1.21% 1.24% 2026-03-31
16 Polar Capital Holdings Plc 1,425,788 $82.85M 1.02% 1.04% 2026-03-31
17 CHARLES SCHWAB INVESTMENT MANAGEMENT INC 1,403,948 $81.58M 1.00% 1.03% 2026-03-31
18 MAVERICK CAPITAL LTD 1,377,738 $80.06M 0.98% 1.01% 2026-03-31
19 EVENTIDE ASSET MANAGEMENT, LLC 1,374,292 $79.84M 0.98% 1.00% 2026-03-31
20 Pivotal bioVenture Partners Investment Advisor LLC 1,372,425 $79.75M 0.98% 1.00% 2026-03-31
21 UBS Group AG Custodian 1,337,390 $77.72M 0.95% 0.98% 2026-03-31
22 GOLDMAN SACHS GROUP INC Custodian 1,275,036 $74.09M 0.91% 0.93% 2026-03-31
23 BANK OF AMERICA CORP /DE/ Custodian 1,216,843 $70.71M 0.87% 0.89% 2026-03-31
24 Bellevue Group AG 1,190,697 $69.19M 0.85% 0.87% 2026-03-31
25 NORTHERN TRUST CORP Custodian 1,144,469 $66.51M 0.82% 0.84% 2026-03-31
11 filers$61.75M notional
# Filer Notional Value % of Total Period
1 Caption Management, LLC $17.61M 28.52% 2026-03-31
2 SUSQUEHANNA INTERNATIONAL GROUP, LLP Custodian $16.00M 25.91% 2026-03-31
3 JANE STREET GROUP, LLC Custodian $13.65M 22.11% 2026-03-31
4 CITADEL ADVISORS LLC Custodian $5.51M 8.92% 2026-03-31
5 DIADEMA PARTNERS LP $3.09M 5.00% 2026-03-31
6 Nantahala Capital Management, LLC $2.05M 3.31% 2026-03-31
7 GOLDMAN SACHS GROUP INC Custodian $1.46M 2.36% 2026-03-31
8 TUDOR INVESTMENT CORP ET AL $1.16M 1.88% 2026-03-31
9 GROUP ONE TRADING LLC Custodian $755.43K 1.22% 2026-03-31
10 Persistent Asset Partners Ltd $323.31K 0.52% 2026-03-31
11 SIMPLEX TRADING, LLC Custodian $151.09K 0.24% 2026-03-31
8 filers$102.74M notional
# Filer Notional Value % of Total Period
1 JANE STREET GROUP, LLC Custodian $33.31M 32.42% 2026-03-31
2 SUSQUEHANNA INTERNATIONAL GROUP, LLP Custodian $25.30M 24.63% 2026-03-31
3 Caption Management, LLC $23.26M 22.63% 2026-03-31
4 BOOTHBAY FUND MANAGEMENT, LLC $11.70M 11.39% 2026-03-31
5 CITADEL ADVISORS LLC Custodian $5.97M 5.81% 2026-03-31
6 SIMPLEX TRADING, LLC Custodian $2.60M 2.53% 2026-03-31
7 GROUP ONE TRADING LLC Custodian $482.31K 0.47% 2026-03-31
8 Walleye Capital LLC $127.84K 0.12% 2026-03-31
Insider Activity
Latest: 2026-08-05
Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
Filed Reporter Role Action Shares Avg Price Net $ Link
2026-08-05 Jim Wassil CHIEF OPERATING OFFICER Mixed — $29.61 -$109.2K EDGAR
2026-08-05 ANDREW GUGGENHIME PRESIDENT AND CFO Mixed — $29.62 -$485.4K EDGAR
2026-08-05 Harpreet S. Dhaliwal Chief Technical Ops Officer Mixed — $39.90 -$513.6K EDGAR
2026-07-28 GRANT PICKERING CHIEF EXECUTIVE OFFICER Mixed −2,000 $30.39 -$979.5K EDGAR
2026-07-16 John Markels Director Grant (A) +23,029 opt — EDGAR
2026-07-06 ANDREW GUGGENHIME PRESIDENT AND CFO Mixed — $31.32 -$519.3K EDGAR
2026-07-06 Jim Wassil CHIEF OPERATING OFFICER Mixed −1,734 $46.82 -$124.0K EDGAR
2026-06-26 GRANT PICKERING CHIEF EXECUTIVE OFFICER Sell (S) −24,237 $55.22 -$1.34M EDGAR
2026-06-23 Moncef Slaoui Director Grant (A) +26,061 opt — EDGAR
2026-06-18 GRANT PICKERING CHIEF EXECUTIVE OFFICER Mixed −24,236 $52.04 -$1.28M EDGAR
2026-06-18 ANDREW GUGGENHIME PRESIDENT AND CFO Mixed — $29.18 -$476.5K EDGAR
2026-06-16 Heath Lukatch Director Award (A) +2,265 — EDGAR
2026-06-16 Halley E Gilbert Director Award (A) +2,265 — EDGAR
2026-06-16 Jacks Lee Director Award (A) +2,265 — EDGAR
2026-06-16 OLIVIER BRANDICOURT Director Award (A) +2,194 — EDGAR
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
Insider Holdings
26 insiders · @ $58.29
Officers, directors, and 10%+ owners ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
# Insider Role Shares Disclosed Exposure Lifetime OM Net Filings Last Filed
1 Peter Kolchinsky 10%+ Owner 5,283,818 $307.99M -$44.98M 1 2020-10-01
2 RA Capital Healthcare Fund LP 10%+ Owner 5,169,254 $301.32M -$54.09M 1 2020-10-09
3 DAVID BONDERMAN 10%+ Owner 5,074,574 $295.80M $37.01M 2 2020-12-17
4 KURT VON EMSTER Director 4,168,718 $242.99M $200.0K 4 2021-06-03
5 Patrick J Heron Director 2,309,554 $134.62M $4.00M 3 2021-06-03
6 Robert Lorne Hopfner Director 1,577,316 $91.94M -$20.55M 11 2021-06-03
7 GRANT PICKERING CHIEF EXECUTIVE OFFICER 586,706 $34.20M -$39.81M 77 2026-07-28
8 ANDREW GUGGENHIME PRESIDENT AND CFO 167,026 $9.74M -$18.70M 49 2026-08-05
9 Jim Wassil CHIEF OPERATING OFFICER 158,930 $9.26M -$10.82M 51 2026-08-05
10 Harpreet S. Dhaliwal Chief Technical Ops Officer 93,756 $5.47M -$1.39M 11 2026-08-05
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
Notice of Proposed Sale (Form 144)
Latest: 2026-08-05
Last 30d: 4 filings · $2.6M notice value  ·  Last 90d: 10 filings · $6.5M notice value · 4 unique filers · 100% under 10b5-1 plans

What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.

How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.

10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.

"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. Amendments (Form 144/A) and post-cancellation refilings can inflate this if you sum naively; the rollup above excludes filings with zero stated value.

Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.

Top 90-day filers: PICKERING GRANT (3, $3.6M) · GUGGENHIME ANDREW (3, $1.6M) · Dhaliwal Harpreet S. (1, $935K) · Wassil Jim (3, $367K)
Filed Filer Role Shares Notice Value Planned Sale Broker Plan Link
2026-08-05 Dhaliwal Harpreet S. Officer 17,000 $935.0K 2026-08-05 UBS Financial Services, Inc. 10b5-1 EDGAR
2026-08-03 GUGGENHIME ANDREW Officer 10,000 $539.9K 2026-08-03 UBS Financial Services, Inc 10b5-1 EDGAR
2026-08-03 Wassil Jim Officer 2,250 $121.5K 2026-08-03 UBS Financial Services, Inc. 10b5-1 EDGAR
2026-07-27 PICKERING GRANT Officer, Director 18,198 $996.7K 2026-07-27 UBS Financial Services, Inc. 10b5-1 EDGAR
2026-07-06 GUGGENHIME ANDREW Officer 10,000 $577.6K 2026-07-06 UBS Financial Services, Inc 10b5-1 EDGAR
2026-07-01 Wassil Jim Officer 2,250 $130.8K 2026-07-01 UBS Financial Services, Inc. 10b5-1 EDGAR
2026-06-26 PICKERING GRANT Officer, Director 24,237 $1.30M 2026-06-26 UBS Financial Services, Inc. 10b5-1 EDGAR
2026-06-18 GUGGENHIME ANDREW Officer 10,000 $530.0K 2026-06-18 UBS Financial Services, Inc 10b5-1 EDGAR
2026-06-18 PICKERING GRANT Officer 24,461 $1.28M 2026-06-18 UBS Financial Services, Inc. 10b5-1 EDGAR
2026-06-01 Wassil Jim Officer 2,250 $114.8K 2026-06-01 UBS Financial Services, Inc. 10b5-1 EDGAR
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed.
ETF Holders
# ETF Provider Weight $ Exposure ETF AUM As Of
Fundamentals

Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.

Metrics
  • Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
  • Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
  • Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
  • Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
  • Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
  • YoY growth — compare to the same quarter a year earlier to remove seasonality.
  • Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
  • Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.

TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.

P/B Ratio3.1
EV/EBITDA-7.4
TTM Net Income$-1.1B
TTM EPS$-7.63
ROE-38.6%